These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 29620259)

  • 21. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Li S; Dai W; Mo W; Li J; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Zhang Q; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Xu L; Guo C
    Int J Cancer; 2017 Dec; 141(12):2571-2584. PubMed ID: 28857200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
    Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
    Gao Y; Li HX; Xu LT; Wang P; Xu LY; Cohen L; Yang PY; Gu K; Meng ZQ
    Mol Biol Rep; 2012 Feb; 39(2):1683-9. PubMed ID: 21617941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y; Yan W; Guo L; Meng C; Li B; Neves H; Chen PC; Li L; Huang Y; Kwok HF; Lin Y
    Mol Med Rep; 2017 Feb; 15(2):941-947. PubMed ID: 28035421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
    Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
    Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
    Sun D; Liu H; Dai X; Zheng X; Yan J; Wei R; Fu X; Huang M; Shen A; Huang X; Ding J; Geng M
    Cancer Lett; 2017 Oct; 406():105-115. PubMed ID: 28687354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
    Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L
    Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275
    [No Abstract]   [Full Text] [Related]  

  • 33. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.